Balyasny Asset Management LLC I Mab Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $415,542 - $926,052	50,247 New	50,247 $568,000
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $135,840 - $223,500	-3,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $171,540 - $253,290	3,000 New	3,000 $217,000
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $1.23 Million - $2.16 Million	-25,731 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $1.14 Million - $1.65 Million	25,731 New	25,731 $1.25 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.